Business Context and Reporting Period
This Form 6-K filing by Linkage Global Inc, a foreign private issuer, covers the month of February 2026. The report details corporate governance changes approved by the Board of Directors on February 10, 2026, effective February 13, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Board Departures: Mr. Zhiyong Wu and Mr. Ryo Fuyunishiki stepped down as Board members. The filing states these departures were not due to any disagreement with the Company regarding operations, policies, or practices.
- Role Continuity: Mr. Fuyunishiki will remain in his position as Chief Operating Officer.
- New Appointment: Dr. Xunyong Zhou was appointed to the Board to serve until the next annual general meeting.
Outlook, Commentary, and Risks
Management Commentary: The Company highlighted Dr. Zhou's extensive background in biotechnology and health innovation, including over 20 patents and experience with enzyme-based theories and AI-enhanced health solutions. He currently serves as a director for Huakang Biomedical Holdings Company Limited and holds leadership roles at Nanjing Hezhen Holding Group Co., Ltd. and Changsha Kerong Health Technology Co., Ltd.
Risks and Contingencies: The filing confirms no family relationships between Dr. Zhou and existing directors or officers and states he was not selected pursuant to any arrangement with other persons. No reportable related party transactions were identified.
Key Facts for Investor Verification
- Confirm the effective date of the Board composition change (February 13, 2026).
- Verify Dr. Xunyong Zhou's current roles at Huakang Biomedical Holdings, Nanjing Hezhen Holding Group, and Changsha Kerong Health Technology.
- Check for any future filings regarding the election of directors at the next annual general meeting.
- Note that this filing contains no financial data; investors should refer to the most recent Form 20-F for financial performance.